catalogue
1、 Review report Page 1 II. Financial statements Page 2-7
(I) consolidated balance sheet Page 2
(II) balance sheet of the parent company Page 3
(III) consolidated income statement Page 4
(IV) profit statement of the parent company Page 5
(V) consolidated cash flow statement Page 6
(VI) cash flow statement of the parent company Page 7
3、 Notes to the financial statements Page 8-18
Review Report
TJS [2022] No. 86
All shareholders of Zhejiang Liansheng Chemical Co., Ltd.:
We have reviewed the attached financial statements of Zhejiang Liansheng Chemical Co., Ltd. (hereinafter referred to as Liansheng Chemical Co., Ltd.) for the fourth quarter of 2021, including the consolidated and parent company’s balance sheet on December 31, 2021, the consolidated and parent company’s income statement from October to December 2021 and January to December 2021, the consolidated and parent company’s cash flow statement from January to December 2021, and the notes to the financial statements. The preparation of these financial statements is the responsibility of the management of Liansheng chemical company. Our responsibility is to issue a review report on these financial statements on the basis of the review work.
We have carried out the review business in accordance with the provisions of the review standards for Chinese certified public accountants No. 2101 – review of financial statements. The standard requires us to plan and implement the review to obtain limited assurance about whether the financial statements are free from material misstatement. The review is mainly limited to asking relevant personnel of Liansheng chemical company and implementing analysis procedures for financial data, and the degree of assurance provided is lower than that of audit. We have not carried out the audit, so we do not express an audit opinion.
According to our review, we have not noticed anything that makes us believe that the financial statements of Liansheng chemical company for the fourth quarter of 2021 have not been prepared in accordance with the provisions of the accounting standards for business enterprises, and have failed to fairly reflect the financial status, operating results and cash flow of Liansheng chemical company and its parent company in all material aspects. Tianjian Certified Public Accountants (special general partnership) Chinese certified public accountant:
Hangzhou, China Certified Public Accountant:
February 10, 2002
Zhejiang Liansheng Chemical Co., Ltd
Notes to financial statements
Q4 2021
Monetary unit: RMB 1. Basic information of the company
Zhejiang Liansheng Chemical Co., Ltd. (hereinafter referred to as the company or the company) was wholly changed and established by Linhai Liansheng Chemical Co., Ltd. in April 2016, and its headquarters is located in Taizhou City, Zhejiang Province. The company now holds a business license with a unified social credit code of 913310826683250245 issued by Taizhou market supervision and Administration Bureau. The registered capital is 81 million yuan, with a total of 81 million shares (par value of 1 yuan per share).
The company is a fine chemical manufacturing industry. Its main business activities are electronic chemicals, pharmaceutical intermediates, pesticide intermediates, and the R & D, production and sales of fine chemicals. Main products: α- Acetyl group- γ- Butyrolactone, cyclopropyl ketone, isopropanol, favelen intermediate-e2, etc.
2、 Statement of compliance with accounting standards for business enterprises
The financial statements prepared by the company comply with the requirements of the accounting standards for business enterprises, the accounting policies adopted are consistent with the financial statements of the previous year, and truly and completely reflect the financial status, operating results, cash flow and other relevant information of the company.
3、 Seasonal / cyclical characteristics of operation
The company’s business activities do not have seasonal and cyclical characteristics.
4、 Notes to items in the consolidated financial statements with special nature or abnormal amount
Note: the amount at the end of the previous year in the notes to the financial statements refers to the amount of financial statements on December 31, 2020, the amount at the end of the period refers to the amount of financial statements on December 31, 2021, the interim period refers to October December 2021, the current year refers to 2021, the comparable interim period of the previous year refers to October December 2020, and the previous year refers to 2020.
（1） Notes to consolidated balance sheet items
1. Accounts receivable
(1) Details
Closing balance
Project book balance bad debt provision
book value
Amount proportion (%)
Bad debt reserves withdrawn by combination 13954078121 100.00718456373 5.1513235621748
Total 13954078121 100.00718456373 5.1513235621748
(Continued)
Amount at the end of last year
Project book balance bad debt provision
book value
Amount proportion (%)
Bad debt reserves withdrawn by portfolio 12745143752 100.00655398900 5.1412089744852
Total 12745143752 100.00655398900 5.1412089744852
(2) Accounts receivable for which bad debt provision is withdrawn according to aging combination
Closing balance at the end of last year
Aging
Withdrawing proportion of bad debt provision of book balance withdrawing proportion of bad debt provision of book balance
Within 1 year 13901165506695058276 5% 12714562207635728110 5%
1-2 years 223310702233107 10% 114823941148239 10%
2-3 years 114823942296479 20%
3-4 years 1153200576600 50%
4-5 years 1153200922560 80%
More than 5 years 1794595117945951 100% 1794595117945951 100%
Subtotal 13954078121718456373 5.15% 12745143752655398900 5.14%
(3) Bad debt provision
Opening balance of the project withdrawn in the current period and transferred back to the closing balance in the current period
Bad debt reserves withdrawn by portfolio 65539890063057473718456373
Subtotal 65539890063057473718456373
(4) Top 5 accounts receivable
Closing balance
Customer name
Proportion of book balance (%) bad debt provision
Bayer Group is 6528716800 46.79326435840
Syngenta 1373963350 9.8568698168
Sankai chemical Japan Co., Ltd. 1152726560 8.2657636328
Shanghai desaino 112 Jiangsu Etern Company Limited(600105) 1 8.0756 Zhuhai Orbita Aerospace Science & Technology Co.Ltd(300053)
DSM nutrition Co., Ltd. 478177500 3.4323908875
Subtotal 10659585261 76.40532979264
For customer units controlled by the same actual controller, accounts receivable are summarized and listed.
2. Inventory
(1) Details
Closing balance at the end of last year
project
Book value of book balance depreciation reserves book value of book balance depreciation reserves
Materials in transit 427794961
Raw materials 36390667996812527535709415243386806135692375073317568628
Products in process 13417571301341757130715045649715045649
Semi finished products 850254303850254303416112165416112165
Goods in stock 210195355711837908919835744681971774541858763451885898196
Issued goods 886244928886244928
Total 7933031789186504364774652742578037783791551138527648664527
(
